BioNTech and MediLink’s HER3 ADC Back In The Game After Safety Concerns

The partners still believe their HER3-targeting ADC can rival Merck & Co and Daiichi Sankyo’s frontrunner, even at a new lower dose range.

Mainz, Rheinland-Pfalz, Germany-9. September 2020 Biontech building in Mainz with the sun shining and waving flags — • Source: Florian Imbusch / Shutterstock.com

BioNTech and MediLink Therapeutics will resume enrolment in a Phase I study of their antibody-drug conjugate, BNT326, in lung and breast cancer patients after a partial hold related to treatment-related deaths was lifted.

BNT326/YL202 is a human epidermal growth factor receptor 3 (HER3)-targeting antibody-drug conjugate (ADC) candidate, a field as yet with no...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

28 Jul 2025

• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

28 Jul 2025

• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Quick Listen: Scrip’s Five Must-Know Things

28 Jul 2025

• By Ian Haydock

In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

25 Jul 2025

• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.